The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther 2018 Feb;18(2):131-148
Date
12/20/2017Pubmed ID
29254387Pubmed Central ID
PMC6121777DOI
10.1080/14737140.2018.1417844Scopus ID
2-s2.0-85043376842 (requires institutional sign-in at Scopus site) 35 CitationsAbstract
Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer related mortality in the United States in 2030, with a 5-year overall survival of less than 10% despite decades of extensive research. Pancreatic cancer is marked by the accumulation of complex molecular changes, complex tumor-stroma interaction, and an immunosuppressive tumor microenvironment. PDAC has proven to be resistant to many cytotoxic, targeted and immunologic treatment approaches. Areas covered: In this paper, we review the major areas of research in PDAC, with highlights on the challenges and areas of opportunity for personalized treatment approaches. Expert commentary: The focus of research in pancreatic cancer has moved away from developing conventional cytotoxic combinations. The marked advances in understanding the molecular biology of this disease especially in the areas of the microenvironment, metabolism, and DNA repair have opened new opportunities for developing novel treatment strategies. Improved understanding of molecular abnormalities allows the development of personalized treatment approaches.
Author List
Tesfaye AA, Kamgar M, Azmi A, Philip PAAuthor
Mandana Kamgar MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaAnimals
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Pancreatic Ductal
Humans
Molecular Targeted Therapy
Pancreatic Neoplasms
Precision Medicine
Survival Rate
Tumor Microenvironment
